Analysts See $-0.15 EPS for Adamis Pharmaceuticals Corporation (ADMP)

March 21, 2018 - By Darrin Black

 Analysts See $ 0.15 EPS for Adamis Pharmaceuticals Corporation (ADMP)

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.15 EPS on March, 29. The stock decreased 4.86% or $0.175 during the last trading session, reaching $3.425. About 690,639 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 21, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. Maxim Group maintained the stock with “Buy” rating in Thursday, July 21 report. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Monday, August 21 by Maxim Group. The firm earned “Buy” rating on Tuesday, December 1 by Maxim Group. Raymond James maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Monday, December 4 with “Buy” rating. As per Tuesday, September 12, the company rating was initiated by Raymond James. The rating was maintained by Maxim Group with “Buy” on Monday, June 12.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $114.36 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: